BIOMED-LUBLIN WYT.SUR.

Research BIOMED-LUBLIN WYT.SUR. (6NQ) on Bullrun: market cap EUR 40.04M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker6NQ
ExchangeF
CountryPoland
SectorHealthcare
IndustryBiotechnology
CurrencyEUR
Market capEUR 40.04M
Financial periodQ1 2026
RevenuePLN 13.61M
Net income-PLN 3.61M
Free cash flowPLN 4.66M
Gross margin52.7%

Valuation Snapshot

latest market cap is EUR 40.04M.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	PLN 42.01M	-PLN 19.93M	-PLN 16.20M	56.1%	n/a	PLN 1.67M	PLN 84.65M	PLN 124.68M

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-08-27	EUR 40.04M	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About BIOMED-LUBLIN WYT.SUR.

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents for use in oncology, gynecology, hematology, immunology, and related therapeutic areas in Poland, the rest of the European Union, and internationally. The company operates through the BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors;

Related stock research

Poland stocks Poland Healthcare stocks A-Z stock index

Other Healthcare stocks

ONCOARENDI THERAP ZY-01 (1B1) Mabion SA (272) Nanogroup SA (NNG) PURE BIOLOGICS ZY -10 (PQB) PolTREG S.A. (PTG) Ryvu Therapeutics SA (RVU) Urteste SA (URT) BIOCELTIX S.A. ZY -10 (XI3) VOXEL SA ZY 1 (0NX) SELVITA S.A. SER.B ZY-80 (787) NEUCA S.A. (7HD) Diagnostyka S.A. (7JS)

Frequently asked questions

What is BIOMED-LUBLIN WYT.SUR.'s market cap?

BIOMED-LUBLIN WYT.SUR.'s market capitalization is EUR 40.04M.